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Immunodeficiency
at the Start of
Combination
Antiretroviral Therapy:
Steady Improvement
or Step Changes?
To the Editors:
The IeDEA and ART-CC Collab-
orations1 recently described CD4 cell
counts at the start of combination anti-
retroviral therapy (cART) in low-, mid-
dle-, and high-income countries. The
ﬁndings accurately highlight the global
problem of HIV-positive individuals ini-
tiating cART at CD4 cell counts below
those recommended currently in the
treatment guidelines in 2002–2010. We
believe, however, that the analysis could
have beneﬁted from 2 main additions.
First, the authors modeled CD4 at
cART initiation linearly. This methodol-
ogy does not allow for the expected
nonlinear changes to CD4 at cART initi-
ation as guidelines changed throughout the
years of analysis. One would expect to see
an increase in CD4 at cART initiation in
2006 and 2009 after changes to WHO
guidelines recommending earlier antiretro-
viral therapy initiation.2 Modeling techni-
ques, such as restricted cubic splines,3
would allow the CD4 at cART initia-
tion to move freely by the year of
cART initiation.
Second, as the authors point out in
the discussion, one possible reason for
lower median CD4 at cART initiation
may be late presentation to HIV care.4
The aim of this work is to aid delivery of
public health strategies and interventions,
so it is important to know if messages
should be geared to more frequent testing
or earlier treatment initiation. It would,
therefore, be useful if the analysis could
be stratiﬁed by those who started cART
shortly after the ﬁrst presentation to HIV
care (eg, at the next visit after the ﬁrst
available CD4) compared with those
under long-term follow-up.
Finally, it should be considered
that median CD4 at initiation in this
analysis is likely to overestimate the true
median at initiation, as those who do not
initiate are not included in this analysis.
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To the Editors:
We thank Ashley Olson et al1 for
their interest in our study of CD4 cell
counts in more than 350,000 patients
who started combination antiretroviral
therapy (ART) from low-, middle-, and
high-income countries during the years
2002–2010,2 based on the Interna-
tional Epidemiological Databases to
Evaluate AIDS3 and the ART Cohort
Collaboration.4 In response to their
ﬁrst point, we found a steady increase
in CD4 cell counts rather than step
changes following the change in WHO
guidelines on when to start ART in
2006 and 2009. We modeled CD4
counts both using additive and linear
mixed-effects models, but there was
virtually no difference in the ﬁt of the 2
models. The effect of the change in the
guidelines was thus gradual, rather
than stepwise. This may be because
of the understandable lag between
a change in WHO guidelines and
individual country-level implementa-
tion resulting in gradual rather than
stepwise increases. Interestingly, our
separate analysis of CD4 measures at
the start of ART in children showed
that trends were clearly nonlinear,
although there was again little evi-
dence of stepwise increases following
guideline changes.5
We agree with Olson et al that the
late presentation for HIV care is one
reason for the late start of ART, and that
stratifying the analysis by the time from
presentation with HIV infection to start of
ART would be interesting. Unfortu-
nately, the date of the ﬁrst presentation
was not generally recorded in the cohorts
participating in the International epide-
miological Databases to Evaluate AIDS.
Also, where recorded, the deﬁnitions of
the ﬁrst presentation varied. Of note, the
ﬁrst presentation will often not have
taken place at the facility where ART
was subsequently initiated.
Finally, we were a bit puzzled
by the correspondents’ statement “that
median CD4 at initiation in this analysis
is likely to overestimate the true median
at initiation, as those who do not initiate
are not included in this analysis.”
Surely, the CD4 count at initiation can
only be studied in patients who initiate
ART. However, as we discussed in our
paper,2 CD4 cell counts at the start of
cART were missing in some patients,
and these patients were more likely to be
from low- and middle-income countries
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and in more advanced stages of HIV
infection than patients with CD4 counts.
It is thus likely that our estimates of
median CD4 cell counts at cART
initiation were biased upward for these
countries.
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